Essential Hypertension
Conditions
Interventions
Olmesartan (max. dose=40 mg/day)-based anti-hypertensive medical therapy
Amlodipine (max. dose=10 mg/day)-based anti-hypertensive medical therapy
Sponsors
Department of Cardiovascular Medicine, Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 50–79 years. 2. Untreated or uncontrolled patients with essential hypertension (systolic BP=>140 mmHg or diastolic BP=>90 mmHg in a sitting position at clinic). 3. No previous medication of ACE inhibitors or ARB within 3 months. 4. Obtained written informed consent.
Exclusion criteria
Exclusion criteria: 1.Cerebrovascular and cardiovascular events including myocardial infarction, cerebral infarction, cerebral hemorrahge and subarchnoidal hemorrahge within 6 months. 2.PTCA or CABG performed within 6 months. 3.Scheduled PTCA or CABG in the future. 4.Congenital or rheumatic heart disease. 5.Severe arrhythmia. 6.Severe liver insufficiency. 7.Severe renal insufficiency. 8.Active cancer or treatment for cancer within 5 years. 9.Pregnancy, possible pregnancy. 10.Not suitable to the clinical trial as judged by a physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) Cardiovascular risk marker levels (2) Changes in cardiovascular risk marker levels | — |
Secondary
| Measure | Time frame |
|---|---|
| Major cardiovascular adverse events (cardiac death, non-fatal myocardial infarction, revascularization or hospitalization by angina, hospitalization by heart failure, cerebrovascular events: cerebral infarction, cerebral hemorrhage, subarchnoidal hemorrhage) | — |
Countries
Japan
Contacts
Public ContactYutaka Furukawa
Kyoto University Hospital Department of Cardiovascular Medicine
Outcome results
None listed